Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 1;3(7):845–853. doi: 10.1016/j.cjco.2021.01.012

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Kaplan-Meier survival estimates. (A) Overall survival for the whole cohort (795 patients): 1-year, 5-year, 6-year, 7-year, and 8-year overall mortality was 25.4%, 59.0%, 64.6%, 67.9%, and 69.2%, respectively. (B) Survival for balloon-expandable and self-expanding groups: 1-year, 5-year, 6-year, 7-year, and 8-year mortality for self-expanding valve group was 25.2%, 58.9%, 64.7%, 68.2%, and 69.5%, respectively; 1-year, 5-year, 6-year, 7-year, and 8-year mortality for balloon-expandable valve group were 26.0%, 59.2%, 64.5%, 66.9%, and 68.0%, respectively. There were no significant differences between the 2 groups at 8 years after TAVR (log-rank test, P = 0.709). (C) Survival for postdilatation and no postdilatation groups: 1-year, 5-year, 6-year, 7-year, and 8-year mortality for postdilatation group was 32.7%, 61.2%, 64.3%, 67.3%, and 69.4%, respectively; 1-year, 5-year, 6-year, 7-year, and 8-year mortality for no-postdilatation group was 24.4%, 58.6%, 64.7%, 68.0%, and 69.2%, respectively. There were no significant differences between the 2 groups at 8 years after TAVR (log-rank test, P = 0.363). TAVR, transcatheter aortic valve replacement.